# Entelos Holding Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/entelos-holding

- Industry: Software
- Headquarters: San Mateo, US
- Website: www.entelos.com
- Total disclosed funding: $40M
- Latest round: Series C (Sep 6, 2001)
- Investors on record: 9

## About

Entelos Holding Corporation specializes in advanced software solutions that enhance drug research and development through predictive modeling capabilities, optimizing clinical trials and patient targeting in the pharmaceutical sector.Entelos Holding Corporation is focused on providing innovative biosimulation software solutions. Founded in San Mateo, US, the company has received a total of USD 16.60 mn in funding through an IPO. The company has completed 8 deals to date, establishing a solid presence in its sector.Entelos Predictive Biosimulation specializes in advanced software solutions designed to enhance drug research and development by providing comprehensive predictive modeling and mapping capabilities. Their core offerings include a sophisticated software platform that simulates system biology of virtual human patients and populations, enabling accurate identification and translation of biomarkers. This technology aids in optimizing clinical trial design, patient stratification, and therapeutic targeting. The company primarily serves pharmaceutical and biotechnology firms engaged in drug development, particularly in areas such as type II diabetes, rheumatoid arthritis, cardiovascular diseases, and dermatology. Entelos operates in various geographical markets, focusing on North America, Europe, and parts of Asia, where these industries are thriving.Entelos generates revenue through a business model centered on B2B transactions, providing software services and expert consulting to its clients in the pharmaceutical and biotechnology sectors. The company engages in partnerships and subscription-based agreements, allowing clients to access its comprehensive biosimulation tools and predictive analytics. Revenue is derived from the deployment of its flagship software platform, which includes mechanism-based mathematical models and biosimulation technology, tailored to each client's specific trial needs. Transactions typically involve structured agreements where clients pay for licenses to utilize the software, along with additional fees for consulting services that provide detailed analysis and modeling support.Entelos Holding Corporation plans to launch new features in its software platform aimed at improving user experience and expanding its capabilities by the end of the next fiscal year. The company is also targeting expansion into Asian markets, particularly Japan and South Korea, by 2025. The recent funding raised through the IPO will be used to support these product development initiatives and enhance marketing efforts in the new geographic regions.

## Funding rounds

- Series C, Sep 6, 2001, $25M — Abingworth, CRV, Boulder Ventures, St. Paul Venture Capital, Brentwood Venture Capital, Earlybird, Compaq Computer Corporation, Bear Stearns Health Innoventures, Equity4Life
- Series B, May 4, 2000, $15M — Abingworth, CRV, Boulder Ventures, St. Paul Venture Capital, Brentwood Venture Capital

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series B, Series C
- CRV (https://capitalatlas.ai/funds/crv) — Series B, Series C
- Boulder Ventures (https://capitalatlas.ai/funds/boulder-ventures) — Series B, Series C
- St. Paul Venture Capital (https://capitalatlas.ai/funds/st-paul-venture-capital) — Series B, Series C
- Brentwood Venture Capital (https://capitalatlas.ai/funds/brentwood-venture-capital) — Series B, Series C
- Earlybird (https://capitalatlas.ai/funds/earlybird) — Series C
- Compaq Computer Corporation — Series C
- Bear Stearns Health Innoventures (https://capitalatlas.ai/funds/bear-stearns-health-innoventures) — Series C
- Equity4Life (https://capitalatlas.ai/funds/equity4life) — Series C